Search

Your search keyword '"Andreas M. Schmitt"' showing total 38 results

Search Constraints

Start Over You searched for: Author "Andreas M. Schmitt" Remove constraint Author: "Andreas M. Schmitt"
38 results on '"Andreas M. Schmitt"'

Search Results

1. Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials

2. Management of Toxicity and Side Effects of Systemic Therapy for Renal Cell Carcinoma

3. Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

4. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials

5. The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days [version 2; peer review: 2 approved]

6. The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days [version 1; peer review: 2 approved]

7. Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials

9. Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer

10. Data from Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways

11. Supplementary Figures S1-S25 from Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways

12. Supplementary Tables S1-S8 from Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways

13. Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma

14. The evidence base of US Food and Drug Administration approvals of novel cancer therapies from 2000 to 2020

16. Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA)

19. Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer

20. Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer

21. Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study

22. Immune responses following third COVID-19 vaccination are reduced in patients with hematologic malignancies compared to patients with solid cancer

23. Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

24. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study

25. Rituximab in primary central nervous system lymphoma—A systematic review and meta‐analysis

26. Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials

27. Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs

29. 1570P Outcome and prognostic factors of COVID-19 infection in cancer patients: Final results of SAKK 80/20

30. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials

31. Characteristics and interpretation of subgroup analyses based on tumour characteristics in randomised trials testing target-specific anticancer drugs: design of a systematic survey

32. 1557O Adaptive immunity to SARS-CoV-2 infection and vaccination in cancer patients: The CAPTURE study

33. Author response for 'Rituximab in Primary Central Nervous System Lymphoma – A Systematic Review and Meta‐analysis'

34. Contrasting Evidence to Reimbursement Reality for Off-label use (OLU) of Drug Treatments in Cancer Care – Rationale and Design of the CEIT-OLU-project

35. Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19

36. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016

37. LBA80 Outcome and prognostic factors of SARS CoV-2 infection in cancer patients: A cross-sectional study (SAKK 80/20 CaSA)

38. OFF-LABEL USE IN LYMPHOMA PATIENTS IN SWITZERLAND

Catalog

Books, media, physical & digital resources